IRADIMED vs Pro Dex
IRADIMED reported revenue of $84 million in fiscal 2025, about the same as Pro Dex's $78 million in fiscal 2026. IRADIMED's revenue grew 14.4% in its latest year, and Pro Dex's grew 16.4%. IRADIMED had an operating margin of 31.2%, against 16.8% at Pro Dex. Free cash flow was $17 million at IRADIMED and $7 million at Pro Dex. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| IRADIMED | Pro Dex | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $84M | $78M |
| Revenue growth | 14.4% | 16.4% |
| Revenue growth a year, last 5 years | 21.5% | 15.3% |
| Gross margin | 76.8% | 31.4% |
| Operating margin | 31.2% | 16.8% |
| Net margin | 26.8% | 17.6% |
| Free cash flow | $17M | $7M |
| Free cash flow margin | 20.5% | 8.7% |
| Return on capital | — | 19.6% |
| Net debt to EBITDA | — | 0.6x |
| Dividends and buybacks | $15M | $3M |
| Change in diluted share count | 0.6% | −1.3% |
| Last close | $81.26 | $63.49 |
| P/E at the last close | 43.5× | 17.5× |
| Insider trades, last 12 months | sold $16.7 million | sold $2.0 million |
| Piotroski F-score | — | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
IRADIMEDPro Dex
Operating margin
Percent of revenue
IRADIMEDPro Dex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IRADIMEDPro Dex